Bệnh cầu thận C3
Tóm tắt
Thuật ngữ
Từ khóa
Tài liệu tham khảo
Walport, 2001, Complement. First of two parts., N Engl J Med, 344, 1058, 10.1056/NEJM200104053441406
Rodríguez de Córdoba, 2004, The human complement factor H: Functional roles, genetic variations and disease associations., Mol Immunol, 41, 355, 10.1016/j.molimm.2004.02.005
Appel, 2005, Membranoproliferative glomerulonephritis type II (dense deposit disease): An update., J Am Soc Nephrol, 16, 1392, 10.1681/ASN.2005010078
Fakhouri, 2010, C3 glomerulopathy: A new classification., Nat Rev Nephrol, 6, 494, 10.1038/nrneph.2010.85
Barbour, 2013, Recent insights into C3 glomerulopathy., Nephrol Dial Transplant, 28, 1685, 10.1093/ndt/gfs430
Gale, 2010, Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis., Lancet, 376, 794, 10.1016/S0140-6736(10)60670-8
Servais, 2012, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies., Kidney Int, 82, 454, 10.1038/ki.2012.63
Sethi, 2012, C3 glomerulonephritis: Clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up., Kidney Int, 82, 465, 10.1038/ki.2012.212
Nasr, 2009, Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients., Clin J Am Soc Nephrol, 4, 22, 10.2215/CJN.03480708
Vernon, 2012, Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency., Am J Kidney Dis, 60, 121, 10.1053/j.ajkd.2012.02.329
Sethi, 2013, Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement., Kidney Int, 83, 293, 10.1038/ki.2012.384
Little, 2006, Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk., Kidney Int, 69, 504, 10.1038/sj.ki.5000084
Licht, 2005, Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15., Am J Kidney Dis, 45, 415, 10.1053/j.ajkd.2004.10.018
Bomback, 2012, Eculizumab for dense deposit disease and C3 glomerulonephritis., Clin J Am Soc Nephrol, 7, 748, 10.2215/CJN.12901211
Daina, 2012, Eculizumab in a patient with dense-deposit disease., N Engl J Med, 366, 1161, 10.1056/NEJMc1112273
McCaughan, 2012, Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies., Am J Transplant, 12, 1046, 10.1111/j.1600-6143.2011.03923.x